Literature DB >> 28157224

Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis.

L Asena1, E Şıngar Özdemir2, A Burcu2, E Ercan1, M Çolak3, D D Altınörs1.   

Abstract

PurposeTo compare the clinical outcome with different treatment regimens in Acute Adenoviral Keratoconjunctivitis (AAK).MethodsThe records of 110 patients diagnosed as AAK in two tertiary eye care centers were evaluated retrospectively. The treatment regimen, follow-up duration, time until improvement of the symptoms, visual acuity, clinical findings, Schirmer's test and the Ocular Surface Disease Index (OSDI) score at the first day, first week and third week were recorded. The Kruskal-Wallis Test and Chi-square test were used for comparison of quantitative and categorical variables, respectively.ResultsForty six patients were receiving topical corticosteroids (Group 1), 32 topical 2% Cyclosporin A (CsA) (Group 2) and 32 only artificial tears (Group 3). Mean time until resolution of the symptoms was lowest in Group 1 (9.5±4.9 days) and highest in Group 3 (13.3±4.2 days)(p: 0.001). OSDI scores at the first and third weeks were highest in Group 3 (52.4±16.4 and 32.3±13.0) and lowest in Group 1 (41.0±21.3 and 23.9±13.2)(p: 0.01 and p: 0.009). At day 21, percentage of the patients with subepthelial infiltrates was the highest in Group 3 (63.4%) and lowest in Group 1 (42.5%).ConclusionsThe symptoms were less severe and had a shorter duration with topical corticosteroids and CsA when compared with palliative therapy. Topical 2% CsA may inhibit development of corneal subepithelial infiltrates when used in the acute phase of infection, similar to corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28157224      PMCID: PMC5437338          DOI: 10.1038/eye.2017.4

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  26 in total

1.  Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis.

Authors:  J T Liegner; R W Yee; J H Wild
Journal:  Am J Ophthalmol       Date:  1990-05-15       Impact factor: 5.258

2.  Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis.

Authors:  Bennie H Jeng; Douglas S Holsclaw
Journal:  Cornea       Date:  2011-09       Impact factor: 2.651

3.  The RPS adeno detector for diagnosing adenoviral conjunctivitis.

Authors:  Robert Sambursky; Shachar Tauber; Frank Schirra; Kristian Kozich; Richard Davidson; Elisabeth J Cohen
Journal:  Ophthalmology       Date:  2006-10       Impact factor: 12.079

4.  Studies of adenovirus type 3 infection treated with methisazone and trifluorothymidine.

Authors:  J M Little; D W Lorenzetti; D C Brown; H H Schweem; B R Jones; H E Kaufman
Journal:  Proc Soc Exp Biol Med       Date:  1968-04

5.  The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study.

Authors:  Jost Hillenkamp; Thomas Reinhard; Rudolf S Ross; Daniel Böhringer; Olaf Cartsburg; Michael Roggendorf; Erik De Clercq; Erhard Godehardt; Rainer Sundmacher
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

6.  A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis.

Authors:  Mark R Wilkins; Sharmina Khan; Catey Bunce; Anthony Khawaja; Dilani Siriwardena; Daniel F P Larkin
Journal:  Br J Ophthalmol       Date:  2011-01-20       Impact factor: 4.638

7.  Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models.

Authors:  Eric G Romanowski; Patricia Pless; Kathleen A Yates; Y Jerold Gordon
Journal:  Cornea       Date:  2005-01       Impact factor: 2.651

8.  Topical cyclosporine A in severe steroid-dependent childhood phlyctenular keratoconjunctivitis.

Authors:  Serge Doan; Eric Gabison; Damien Gatinel; Minh-Hanh Duong; Olivia Abitbol; Thanh Hoang-Xuan
Journal:  Am J Ophthalmol       Date:  2006-01       Impact factor: 5.258

9.  [The effects of topical steroids in epidemic kerato-conjunctivitis (author's transl)].

Authors:  S Trauzettel-Klosinski; R Sundmacher; R Wigand
Journal:  Klin Monbl Augenheilkd       Date:  1980-06       Impact factor: 0.700

10.  A prospective, masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis.

Authors:  J B Ward; L G Siojo; S G Waller
Journal:  Cornea       Date:  1993-05       Impact factor: 2.651

View more
  6 in total

1.  Cyclosporine in ocular surface inflammation.

Authors:  P Hossain
Journal:  Eye (Lond)       Date:  2017-02-17       Impact factor: 3.775

Review 2.  Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.

Authors:  Su-Hsun Liu; Barbara S Hawkins; Sueko M Ng; Mark Ren; Louis Leslie; Genie Han; Irene C Kuo
Journal:  Cochrane Database Syst Rev       Date:  2022-03-03

3.  Determinants of Outcomes of Adenoviral Keratoconjunctivitis.

Authors:  Cecilia S Lee; Aaron Y Lee; Lakshmi Akileswaran; David Stroman; Kathryn Najafi-Tagol; Steve Kleiboeker; James Chodosh; Amalia Magaret; Anna Wald; Russell N Van Gelder
Journal:  Ophthalmology       Date:  2018-03-27       Impact factor: 12.079

Review 4.  Mystery eye: Human adenovirus and the enigma of epidemic keratoconjunctivitis.

Authors:  Rahul A Jonas; Lawson Ung; Jaya Rajaiya; James Chodosh
Journal:  Prog Retin Eye Res       Date:  2019-12-28       Impact factor: 21.198

5.  Bilateral disciform keratitis of presumed adenoviral etiology.

Authors:  Rana Altan-Yaycioglu; Serkan Poyraz
Journal:  Indian J Ophthalmol       Date:  2018-01       Impact factor: 1.848

6.  Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis.

Authors:  Rahul Bhargava; Prachi Kumar
Journal:  Indian J Ophthalmol       Date:  2019-05       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.